• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

    11/6/24 1:20:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVO alert in real time by email
    • Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions

    • Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships

    • Successful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutions

    • Priority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated

    HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate updates for the third quarter of 2024, highlighting strategic progress across key partnerships and operations.

    Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "We continue to deliver on the successful execution of our Priority Reset and have achieved significant progress across key initiatives. New and extended partnerships clearly underscore Evotec's enduring leadership in R&D and precision medicine. Building on this exceptionally strong foundation, we are now laying the groundwork for an accelerated transformation program that will pave the way for long-term profitable growth. While the challenging market environment has impacted near-term results, we are seeing strong momentum across strategic priorities and look forward to reporting back on our progress in early 2025."

    Challenging market conditions weigh on Shared R&D, while Just - Evotec Biologics delivers strong growth

    • Group revenues decreased by (1)% to € 575.7 m (9M 2023: € 580.1 m)

    • Total Shared R&D revenues decreased by (12)% to € 447.1 m (9M 2023: € 506.1 m, due to a challenging market environment

    • Evotec's Just - Evotec Biologics segment saw impressive growth, with revenues rising by 74% year-over-year, contributing €128.7 m (9M 2023: € 74.1 m) to the overall topline

    • Adjusted Group EBITDA totalled € (6.0) m (9M 2023: € 50.2 m) driven by a mismatch between revenues and cost base in the Shared R&D segment as well as costs related to the expansion of operations of Just - Evotec Biologics

    • Core business activities in Shared R&D as well as Just - Evotec Biologics reached break-even

    Transformation Process on track with significant savings realised

    • Priority Reset is set to yield an annualised adjusted EBITDA improvement of over € 40 m, starting H2 2024

    • Successful implementation of measures to improve liquidity

    • One-off costs related to Priority Reset measures recognised at € 62.3 m as of Q3, lower than initial provision of € 68.5 m on 30 June 2024

    • Strategic Review process initiated to examine status quo and deliver performance and productivity improvements as part of transformation for long-term profitable growth

    New and expanded partnerships

    • Extension and expansion of tech partnership with Sandoz for development and commercial manufacturing of biosimilars

    • Extension of collaboration with Bristol Myers Squibb ("BMS") based on targeted protein degradation into indications outside of oncology, triggering programme-based payment of US$ 50 m to fund further research

    • Further progress made in strategic neuroscience collaboration with Bristol Myers Squibb, payments of US$ 25 m received

    • Strong progress in strategic protein degradation partnership with Bristol Myers Squibb, resulted in reception of performance-based and programme-based payments of in total US$ 75 m

    • New technology development partnership with Novo Nordisk to support next-generation cell therapies

    • New multi-year master research collaboration and option and license agreement with Pfizer, initially focusing on early discovery research for metabolic and infectious diseases

    • Collaboration with X-Chem to access DNA-encoded library ("DEL") to expand hit-finding options

    Operational milestone achieved

    • Opening of cutting-edge biologics facility J.POD in Toulouse, France (EU) on 20 September 2024 marks significant expansion of European production capabilities and strengthens position in the biologics market.

    Business Outlook for full-year 2024

    • Group revenues1) expected in the range of € 790 - 820 m (2023: € 781.4 m).

    • R&D expenditures are expected in a range of € 50 - 60 m (2023: € 64.8 m).

    • Adjusted Group EBITDA1) is expected to reach € 15 - 35 m (2023: € 66.4 m).

    1) Guidance including future non-core activities

    More detailed information and financial tables are available in the half-year report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications

    Webcast/Conference Call

    The Company plans to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.

    Webcast details

    Date: Wednesday, 06 November 2024

    Time: 2.00 pm CET (01.00 pm BT, 08.00 am ET)

    To join the audio webcast and to access the presentation slides, please register via this link.

    The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications.

    Conference call details

    To join via phone, please pre-register via this link.

    You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

    A simultaneous slide presentation for participants dialing in via phone is available under this link.

    About Evotec SE

    Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

    Forward-looking-statements

    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    For further information, please contact:

    Investor Relations

    Volker Braun
    EVP Head of Global Investor Relations & ESG
    [email protected]

    Media

    Susanne Kreuter
    VP Head of Strategic Marketing
    [email protected]

    SOURCE: Evotec SE



    View the original press release on accesswire.com

    Get the next $EVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVO

    DatePrice TargetRatingAnalyst
    4/24/2025Sell → Hold
    Deutsche Bank
    10/7/2024Buy → Hold
    Jefferies
    8/8/2024Hold → Sell
    Deutsche Bank
    7/29/2024$15.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    7/11/2024Buy → Hold
    Deutsche Bank
    4/12/2024Hold → Buy
    Deutsche Bank
    1/18/2024Sector Perform → Outperform
    RBC Capital Mkts
    6/23/2023$12.00 → $16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $EVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

      Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat l

      1/22/25 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

      Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((SDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from acade

      12/11/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec Announces Change in Management Board

      Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Managemen

      11/29/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Financials

    Live finance-specific insights

    See more
    • Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

      Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda

      11/6/24 1:20:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

      HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we

      10/30/24 3:30:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

      Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G

      8/14/24 1:30:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evotec SE upgraded by Deutsche Bank

      Deutsche Bank upgraded Evotec SE from Sell to Hold

      4/24/25 7:18:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE downgraded by Jefferies

      Jefferies downgraded Evotec SE from Buy to Hold

      10/7/24 7:52:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE downgraded by Deutsche Bank

      Deutsche Bank downgraded Evotec SE from Hold to Sell

      8/8/24 8:58:18 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Evotec SE

      SC 13D - Evotec SE (0001412558) (Subject)

      11/8/24 9:43:55 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evotec SE (Amendment)

      SC 13G/A - Evotec SE (0001412558) (Subject)

      2/14/24 4:55:09 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evotec SE (Amendment)

      SC 13G/A - Evotec SE (0001412558) (Subject)

      2/2/23 1:24:31 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

      Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm

      9/26/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE: Results of the Annual General Meeting 2024

      Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina

      6/10/24 12:15:00 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

      HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of

      4/23/24 3:00:00 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    SEC Filings

    See more
    • SEC Form 6-K filed by Evotec SE

      6-K - Evotec SE (0001412558) (Filer)

      5/6/25 6:00:17 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Evotec SE

      20-F - Evotec SE (0001412558) (Filer)

      4/17/25 6:05:32 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Evotec SE

      6-K - Evotec SE (0001412558) (Filer)

      4/17/25 6:02:39 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care